Read by QxMD icon Read

Plasmodium vivax and treatment

Yang Cheng, Feng Lu, Bo Wang, Jian Li, Jin-Hee Han, Daisuke Ito, Deok-Hoon Kong, Lubin Jiang, Jian Wu, Kwon-Soo Ha, Eizo Takashima, Jetsumon Sattabongkot, Jun Cao, Myat Htut Nyunt, Myat Phone Kyaw, Sanjay A Desai, Louis H Miller, Takafumi Tsuboi, Eun-Taek Han
Plasmodium vivax, a major agent of malaria in both temperate and tropical climates, has been thought to be unable to infect humans lacking the Duffy (Fy) blood group antigen because this receptor is critical for erythrocyte invasion. Recent surveys in various endemic regions, however, have reported P. vivax infections in Duffy-negative individuals, suggesting that the parasite may utilize alternative receptor-ligand pairs to complete the erythrocyte invasion. Here, we identified and characterized a novel parasite ligand, Plasmodium vivax GPI-anchored micronemal antigen (PvGAMA), that bound human erythrocytes regardless of Duffy antigen status...
October 19, 2016: Scientific Reports
Jung Yoon, Seung Gyu Yun, Jeeyong Kim, Yoo Na Jung, Young Eun Koh, Jeong Hun Nam, Eun Taek Han, Chae Seung Lim
We evaluated the diagnostic usefulness of the LH780 Coulter blood cell counter for detection and therapeutic monitoring of malaria including cross-reactivity with nucleated RBC (NRBC) samples. A total of 405 patients (43 patients with Plasmodium vivax malaria and the control group of 120 healthy subjects, 111 patients with fever, and 131 patients with NRBCs) were analyzed with routine CBC using the LH780. We analyzed the CBC results according to three selected parameters: an abnormal peak in the WBC histogram before 35fL, the presence of red dots in the nonwhite cell zone of 2D WBC Diff Dataplot, and platelet-related flags suggesting platelet clumps or giant platelets...
October 14, 2016: Acta Tropica
J Kevin Baird, Neena Valecha, Stephan Duparc, Nicholas J White, Ric N Price
The diagnosis and treatment of Plasmodium vivax malaria differs from that of Plasmodium falciparum malaria in fundamentally important ways. This article reviews the guiding principles, practices, and evidence underpinning the diagnosis and treatment of P vivax malaria.
October 5, 2016: American Journal of Tropical Medicine and Hygiene
Toby Leslie, Sami Nahzat, Walid Sediqi
Around half of the population of Afghanistan resides in areas at risk of malaria transmission. Two species of malaria (Plasmodium vivax and Plasmodium falciparum) account for a high burden of disease-in 2011, there were more than 300,000 confirmed cases. Around 80-95% of malaria is P. vivax Transmission is seasonal and focal, below 2,000 m in altitude, and in irrigated areas which allow breeding of anopheline mosquito vectors. Malaria risk is stratified to improve targeting of interventions. Sixty-three of 400 districts account for ∼85% of cases, and are the target of more intense control efforts...
October 5, 2016: American Journal of Tropical Medicine and Hygiene
Justin A Green, Khadeeja Mohamed, Navin Goyal, Samia Bouhired, Azra Hussaini, Siôn W Jones, Gavin C K W Koh, Ivan Kostov, Maxine Taylor, Allen Wolstenholm, Stephan Duparc
Tafenoquine is in development as a single-dose treatment for relapse prevention in Plasmodium vivax malaria. Tafenoquine must be co-administered with a blood schizonticide; either chloroquine or artemisinin-based combination therapy (ACT). This open-label, randomized, parallel-group study evaluated potential drug interactions between tafenoquine and two ACTs: dihydroartemisinin-piperaquine or artemether-lumefantrine. Healthy volunteers of either sex, aged 18-65 years, without glucose-6-phosphate dehydrogenase deficiency, were randomized into five cohorts (n=24 per cohort) to receive tafenoquine on day 1 (300 mg) plus: once daily dihydroartemisinin-piperaquine on days 1, 2 and 3 (120:960 mg for 36-<75 kg bodyweight; 160:1280 mg for ≥75-100 kg bodyweight); or artemether-lumefantrine (80:480 mg) two doses 8 h apart on day 1, then twice daily on days 2 and 3; or each drug given alone...
October 3, 2016: Antimicrobial Agents and Chemotherapy
Anju Verma, Hema Joshi, Vineeta Singh, Anup Anvikar, Neena Valecha
BACKGROUND: Plasmodium vivax is the most widely distributed human malaria parasite and accounts for approximately the same number of malaria cases as Plasmodium falciparum in India. Compared with P. falciparum, P. vivax is difficult to eradicate because of its tendency to cause relapses, which impacts treatment and control strategies. The genetic diversity of these parasites, particularly of the merozoite surface protein-3 alpha (msp-3α) gene, can be used to help develop a potential vaccine...
2016: Malaria Journal
Chao Xu, Qing-Kuan Wei, Jin Li, Ting Xiao, Kun Yin, Chang-Lei Zhao, Yong-Bin Wang, Xiang-Li Kong, Gui-Hua Zhao, Hui Sun, Xin Liu, Bing-Cheng Huang
Malaria remains a serious public health problem in Shandong Province, China; therefore, it is important to explore the characteristics of the current malaria prevalence situation in the province. In this study, data of malaria cases reported in Shandong during 2012-2014 were analyzed, and Plasmodium species were confirmed by smear microscopy and nested-PCR. A total of 374 malaria cases were reported, 80.8% of which were reported from 6 prefectures. Of all cases, P. falciparum was dominant (81.3%), followed by P...
August 2016: Korean Journal of Parasitology
Ravi Bhatia, Dinesh Rajwaniya, Priti Agrawal
Although malaria is endemic in India, congenital malaria is not very common. Congenital malaria is a very rare condition in both endemic and nonendemic areas. We report a case of congenital malaria in a six-day-old neonate with fever and splenomegaly. The diagnosis was picked up accidentally on a peripheral smear examination. Congenital malaria should be kept as differential diagnosis of neonatal sepsis. Timely detection of this condition could lead to early diagnosis and treatment, thereby preventing neonatal mortality...
2016: Case Reports in Pediatrics
Margaret A Phillips, Karen L White, Sreekanth Kokkonda, Xiaoyi Deng, John White, Farah El Mazouni, Kennan Marsh, Diana R Tomchick, Krishne Manjalanagara, Kakali Rani Rudra, Grennady Wirjanata, Rintis Noviyanti, Ric N Price, Jutta Marfurt, David M Shackleford, Francis C K Chiu, Michael Campbell, Maria Belen Jimenez-Diaz, Santiago Ferrer Bazaga, Iñigo Angulo-Barturen, Maria Santos Martinez, Maria Lafuente-Monasterio, Werner Kaminsky, Kigbafori Silue, Anne-Marie Zeeman, Clemens Kocken, Didier Leroy, Benjamin Blasco, Emilie Rossignol, Thomas Rueckle, Dave Matthews, Jeremy N Burrows, David Waterson, Michael J Palmer, Pradipsinh K Rathod, Susan A Charman
The emergence of drug-resistant malaria parasites continues to hamper efforts to control this lethal disease. Dihydroorotate dehydrogenase has recently been validated as a new target for the treatment of malaria, and a selective inhibitor (DSM265) of the Plasmodium enzyme is currently in clinical development. With the goal of identifying a backup compound to DSM265, we explored replacement of the SF5-aniline moiety of DSM265 with a series of CF3-pyridinyls while maintaining the core triazolopyrimidine scaffold...
October 4, 2016: ACS Infectious Diseases
Dhelio Pereira, André Daher, Graziela Zanini, Ivan Maia, Lais Fonseca, Luciana Pitta, Rosilene Ruffato, Paola Marchesini, Cor Jesus Fontes
BACKGROUND: Malaria remains a major public health problem, with half the world population at risk of contracting malaria. The effects of Plasmodium vivax on prosperity and longevity have been highlighted in several recent clinical case reports. The first line of vivax treatment drugs has seen no radical innovation for more than 60 years. This study introduces a subtle incremental innovation to vivax treatment: a chloroquine and primaquine co-blister. The co-blister includes a new chloroquine formulation incorporating coated tablets to mask the drug's bitter taste and user-friendly packaging containing tablets of each drug, which may improve patient adherence and facilitate the appropriate use of the drugs...
2016: Malaria Journal
Gurjeet Singh, Raksha Singh, Anant Dattatraya Urhehar
INTRODUCTION: Malaria is a human disease of which causes high morbidity and mortality. In Plasmodium falciparum malaria, the resistance to antimalarial drugs, especially chloroquine (CQ) is one of the paramount factors contributing to the global increase in morbidity and mortality, due to malaria. Hence, there is a need for detection of chloroquine drug resistance genes i.e., pfcrt-o (Plasmodium falciparum chloroquine resistance transporter-o) and pfmdr-1 (Plasmodium falciparum multidrug resistance-1) of P...
July 2016: Journal of Clinical and Diagnostic Research: JCDR
Bridget E Barber, Timothy William, Matthew J Grigg, Kim A Piera, Youwei Chen, Hao Wang, J Brice Weinberg, Tsin W Yeo, Nicholas M Anstey
BACKGROUND:  Pathogenesis of severe Plasmodium vivax malaria is poorly understood. Endothelial dysfunction and reduced nitric-oxide (NO) bioavailability characterise severe falciparum malaria, but have not been assessed in severe vivax malaria. METHODS:  In patients with severe (n=9) and non-severe (n=58) vivax malaria, and in healthy controls (HCs, N=79) we measured NO-dependent endothelial function using reactive hyperemia-peripheral arterial tonometry (RH-PAT), and assessed associations with arginine, asymmetric dimethylarginine (ADMA) and haemolysis...
September 13, 2016: Journal of Infectious Diseases
Yuanyuan Cao, Weiming Wang, Yaobao Liu, Chris Cotter, Huayun Zhou, Guoding Zhu, Jianxia Tang, Feng Tang, Feng Lu, Sui Xu, Yaping Gu, Chao Zhang, Julin Li, Jun Cao
BACKGROUND: Following initiation of China's National Malaria Elimination Action Plan in 2010, indigenous malaria infections in Jiangsu Province decreased significantly. Meanwhile imported Plasmodium infections have increased substantially, particularly Plasmodium ovale and Plasmodium malariae. Given the risk for malaria resurgence, there is an urgent need to understand the increase in imported P. ovale and P. malariae infections as China works to achieve national malaria elimination. METHODS: An observational study of imported malaria cases in Jiangsu Province, China was carried out for the period of 2011-2014...
2016: Malaria Journal
Rhea J Longley, Piyarat Sripoorote, Pornpimol Chobson, Teerawat Saeseu, Chonlaphat Sukasem, Suparat Phunanukoonnon, Wang Nguitragool, Ivo Mueller, Jetsumon Sattabongkot
Primaquine is the only licensed antimalarial drug that is capable of clearing dormant Plasmodium vivax liver stage parasites. To date, there is no clear evidence of resistance of the liver stage parasite against this drug, because of the difficulty in ascertaining the cause of recurrent infection. We followed 52 Thai P. vivax patients for 9 months after directly observed treatment of 15 mg primaquine daily for 14 days. Blood samples taken at 2-4 weekly intervals were assessed by microscopy and polymerase chain reaction (PCR) for the presence of parasites...
September 6, 2016: American Journal of Tropical Medicine and Hygiene
Habtamu Bedimo Beyene, Melkamu Bedimo Beyene, Yehenew Asmamaw Ebstie, Zelalem Desalegn
BACKGROUND: Resistance to anti-malarials is a major challenge for effective malaria control in sub-Saharan Africa. This triggered a need for routine monitoring of the efficacy of the antimalarial drugs every two years in all malaria endemic countries. Chloroquine remained the drug of choice for the treatment of vivax malaria in Ethiopia. Though, a strong scientific evidence of chloroquine resistance to P.vivax that could have brought change of treatment regimen is yet to be established in Ethiopia, continuous and regular monitoring of drug's efficacy is critical for establishing rational anti-malarial drug policies...
2016: PloS One
A B Biswas, Sarmila Mallik, Dipta Kanti Mukhopadhyay, Aditya Prasad Sarkar, Susmita Nayak, Asit Kumar Biswas
BACKGROUND: Early diagnosis and effective treatment are the key areas in malaria control in India. OBJECTIVE: The present study was carried out to assess the knowledge and skill of health personnel at primary care level and the logistic support related to the program at subcenter (SC) level. METHODS: A cross-sectional, descriptive study was conducted among medical and paramedical personnel working at primary health-care institutions in two districts of West Bengal...
July 2016: Indian Journal of Public Health
Suiane Negreiros, Samela Farias, Giselle Maria Rachid Viana, Sheila Akinyi Okoth, Stella M Chenet, Thayna Maria Holanda de Souza, Paola Marchesini, Venkatachalam Udhayakumar, Marinete Marins Povoa, Ana Carolina Faria E Silva Santelli, Alexandre Macedo de Oliveira
We evaluated the efficacy of chloroquine and primaquine on uncomplicated Plasmodium vivax malaria in Cruzeiro do Sul, Brazil, in 2014. Patients ≥ 5 years of age with either fever or history of fever, and laboratory-confirmed P. vivax monoinfection received chloroquine (total dose = 25 mg/kg) and primaquine (total dose = 3.5 mg/kg), and were followed up for 168 days (24 weeks). We used microsatellite genotyping to differentiate recurrent infections caused by heterologous parasites from those caused by homologous ones...
August 22, 2016: American Journal of Tropical Medicine and Hygiene
Cindy S Chu, Nicholas J White
INTRODUCTION: Relapses are important contributors to illness and morbidity in Plasmodium vivax and P. ovale infections. Relapse prevention (radical cure) with primaquine is required for optimal management, control and ultimately elimination of Plasmodium vivax malaria. A review was conducted with publications in English, French, Portuguese and Spanish using the search terms 'P. vivax' and 'relapse'. AREAS COVERED: Hypnozoites causing relapses may be activated weeks or months after initial infection...
October 2016: Expert Review of Anti-infective Therapy
Yehenew A Ebstie, Solomon M Abay, Wondmagegn T Tadesse, Dawit A Ejigu
Despite declining global malaria incidence, the disease continues to be a threat to people living in endemic regions. In 2015, an estimated 214 million new malaria cases and 438,000 deaths due to malaria were recorded. Plasmodium vivax is the second most common cause of malaria next to Plasmodium falciparum. Vivax malaria is prevalent especially in Southeast Asia and the Horn of Africa, with enormous challenges in controlling the disease. Some of the challenges faced by vivax malaria-endemic countries include limited access to effective drugs treating liver stages of the parasite (schizonts and hypnozoites), emergence/spread of drug resistance, and misperception of vivax malaria as nonlethal...
2016: Drug Design, Development and Therapy
Ahmet Özbilgin, İbrahim Çavuş, Ahmet Yıldırım, Cumhur Gündüz
Plasmodium knowlesi is now added to the known four Plasmodium species (P.vivax, P.falciparum, P.malariae, P.ovale) as a cause of malaria in humans because of the recent increasing rate of cases reported from countries of southeastern Asia. P.knowlesi which infects macaque monkeys (Macaca fascicularis and M.nemestrina) is transmitted to humans especially by Anopheles leucosphyrus and An.hackeri mosquitos. First human cases of P.knowlesi malaria have been detected in Malaysia which have reached high numbers in recent years and also have been reported from countries of Southeast Asia such as Thailand, Philippines, Myanmar, Singapore and Vietnam...
July 2016: Mikrobiyoloji Bülteni
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"